Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the selection of HER3-directed ADCs to treat advanced solid tumors, based on available evidence.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related